Baxdrostat: A Breakthrough Drug for Resistant Hypertension in India

Baxdrostat, a new blood pressure pill, has been hailed as a breakthrough for patients with resistant hypertension. The Phase III BaxHTN trial showed that Baxdrostat reduced systolic blood pressure by an additional 9-10 mmHg compared to placebo. Experts believe it could particularly benefit Indian patients, where resistant hypertension is often driven by undiagnosed aldosterone excess. The drug is expected to be launched in India soon, giving doctors a new option for millions with uncontrolled blood pressure.

AstraZeneca's Phase III trial for baxdrostat, a blood pressure medication, has yielded positive results, leading to a significant increase in shares for Mineralys Therapeutics. The trial, known as BaxHTN, demonstrated that baxdrostat reduced systolic blood pressure (SBP) by an additional 9.8 mmHg compared to placebo, with a 15.7 mmHg reduction from baseline [1].

The trial enrolled 796 patients and was presented at the European Society of Cardiology Congress 2025 and published in the New England Journal of Medicine. The results suggest that baxdrostat could be effective in managing resistant hypertension, a condition where standard treatments fail to control blood pressure. This is particularly relevant in India, where undiagnosed aldosterone excess is a common driver of resistant hypertension [1].

Mineralys Therapeutics is developing lorundrostat, a drug similar to baxdrostat, for the treatment of resistant hypertension. The positive results from the BaxHTN trial bolster investor confidence in lorundrostat's potential. The company's shares surged by approximately 85% following the announcement of the trial results [1].

In a separate development, Mineralys Therapeutics presented subgroup analyses from its Phase 3 Launch-HTN trial, which enrolled a diverse group of participants with uncontrolled or resistant hypertension. The trial demonstrated significant and clinically meaningful blood pressure reductions across all participant subgroups, including Black or African American adults, older adults, women, and participants with comorbid obesity [2].

These findings highlight the potential of lorundrostat to address a critical unmet medical need and improve blood pressure control in high-risk patient cohorts. Mineralys Therapeutics is moving forward with a New Drug Application (NDA) filing strategy and plans to file the NDA in the fourth quarter of 2025 or the first quarter of 2026 [2].

References:
[1] https://www.astrazeneca.com/media-centre/press-releases/2025/baxdrostat-demonstrated-statistically-significant-clinically-meaningful-reduction-sbp-patients-hard-control-hypertension-baxhtn-phase-iii-trial.html
[2] https://www.biospace.com/press-releases/mineralys-therapeutics-presents-subgroup-analyses-of-phase-3-launch-htn-trial-demonstrating-efficacy-and-safety-of-lorundrostat-in-hypertension-participants-with-high-unmet-medical-need